nodes	percent_of_prediction	percent_of_DWPC	metapath
Aprepitant—TACR1—vagus nerve—esophageal cancer	0.0656	0.465	CbGeAlD
Aprepitant—TACR3—smooth muscle tissue—esophageal cancer	0.0244	0.173	CbGeAlD
Aprepitant—TACR1—smooth muscle tissue—esophageal cancer	0.00943	0.0669	CbGeAlD
Aprepitant—TACR1—trachea—esophageal cancer	0.00866	0.0614	CbGeAlD
Aprepitant—TACR1—digestive system—esophageal cancer	0.00745	0.0528	CbGeAlD
Aprepitant—TACR1—lung—esophageal cancer	0.00622	0.0441	CbGeAlD
Aprepitant—TACR1—lymph node—esophageal cancer	0.00425	0.0302	CbGeAlD
Aprepitant—CYP2C19—digestive system—esophageal cancer	0.00284	0.0202	CbGeAlD
Aprepitant—CYP1A2—digestive system—esophageal cancer	0.00232	0.0165	CbGeAlD
Aprepitant—CYP3A5—digestive system—esophageal cancer	0.00224	0.0159	CbGeAlD
Aprepitant—CYP2C9—digestive system—esophageal cancer	0.00221	0.0156	CbGeAlD
Aprepitant—CYP1A2—lung—esophageal cancer	0.00194	0.0138	CbGeAlD
Aprepitant—CYP3A5—lung—esophageal cancer	0.00187	0.0133	CbGeAlD
Aprepitant—CYP3A4—digestive system—esophageal cancer	0.00168	0.0119	CbGeAlD
Aprepitant—Pulmonary embolism—Methotrexate—esophageal cancer	0.0015	0.00315	CcSEcCtD
Aprepitant—Neuropathy peripheral—Cisplatin—esophageal cancer	0.0015	0.00315	CcSEcCtD
Aprepitant—Myocardial infarction—Cisplatin—esophageal cancer	0.0015	0.00315	CcSEcCtD
Aprepitant—Lethargy—Capecitabine—esophageal cancer	0.0015	0.00313	CcSEcCtD
Aprepitant—Stomatitis—Cisplatin—esophageal cancer	0.00149	0.00313	CcSEcCtD
Aprepitant—Conjunctivitis—Cisplatin—esophageal cancer	0.00149	0.00312	CcSEcCtD
Aprepitant—Hyponatraemia—Capecitabine—esophageal cancer	0.00147	0.00308	CcSEcCtD
Aprepitant—Osteoarthritis—Capecitabine—esophageal cancer	0.00147	0.00307	CcSEcCtD
Aprepitant—Depressed level of consciousness—Methotrexate—esophageal cancer	0.00145	0.00304	CcSEcCtD
Aprepitant—Bradycardia—Cisplatin—esophageal cancer	0.0014	0.00293	CcSEcCtD
Aprepitant—Blood creatinine increased—Capecitabine—esophageal cancer	0.00137	0.00288	CcSEcCtD
Aprepitant—Dehydration—Capecitabine—esophageal cancer	0.00136	0.00286	CcSEcCtD
Aprepitant—Urine output increased—Methotrexate—esophageal cancer	0.00136	0.00285	CcSEcCtD
Aprepitant—Neoplasm—Methotrexate—esophageal cancer	0.00136	0.00285	CcSEcCtD
Aprepitant—Urinary tract disorder—Cisplatin—esophageal cancer	0.00136	0.00285	CcSEcCtD
Aprepitant—Connective tissue disorder—Cisplatin—esophageal cancer	0.00135	0.00283	CcSEcCtD
Aprepitant—Urethral disorder—Cisplatin—esophageal cancer	0.00135	0.00283	CcSEcCtD
Aprepitant—Abdominal pain upper—Capecitabine—esophageal cancer	0.00134	0.00281	CcSEcCtD
Aprepitant—Hypokalaemia—Capecitabine—esophageal cancer	0.00133	0.0028	CcSEcCtD
Aprepitant—Breast disorder—Capecitabine—esophageal cancer	0.00132	0.00278	CcSEcCtD
Aprepitant—Toxic epidermal necrolysis—Capecitabine—esophageal cancer	0.00132	0.00277	CcSEcCtD
Aprepitant—Aspartate aminotransferase increased—Capecitabine—esophageal cancer	0.00132	0.00277	CcSEcCtD
Aprepitant—Gastritis—Capecitabine—esophageal cancer	0.0013	0.00272	CcSEcCtD
Aprepitant—Muscular weakness—Capecitabine—esophageal cancer	0.00129	0.00271	CcSEcCtD
Aprepitant—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.00129	0.00271	CcSEcCtD
Aprepitant—Eye disorder—Cisplatin—esophageal cancer	0.00129	0.00269	CcSEcCtD
Aprepitant—Tinnitus—Cisplatin—esophageal cancer	0.00128	0.00269	CcSEcCtD
Aprepitant—Cardiac disorder—Cisplatin—esophageal cancer	0.00128	0.00268	CcSEcCtD
Aprepitant—Flushing—Cisplatin—esophageal cancer	0.00128	0.00268	CcSEcCtD
Aprepitant—Abdominal distension—Capecitabine—esophageal cancer	0.00128	0.00267	CcSEcCtD
Aprepitant—Dysphagia—Capecitabine—esophageal cancer	0.00127	0.00265	CcSEcCtD
Aprepitant—Thrombophlebitis—Methotrexate—esophageal cancer	0.00126	0.00264	CcSEcCtD
Aprepitant—Diabetes mellitus—Methotrexate—esophageal cancer	0.00125	0.00263	CcSEcCtD
Aprepitant—Photosensitivity—Methotrexate—esophageal cancer	0.00124	0.0026	CcSEcCtD
Aprepitant—Polyuria—Methotrexate—esophageal cancer	0.00124	0.0026	CcSEcCtD
Aprepitant—Immune system disorder—Cisplatin—esophageal cancer	0.00124	0.0026	CcSEcCtD
Aprepitant—Mediastinal disorder—Cisplatin—esophageal cancer	0.00124	0.0026	CcSEcCtD
Aprepitant—Sweating increased—Capecitabine—esophageal cancer	0.00123	0.00259	CcSEcCtD
Aprepitant—Alopecia—Cisplatin—esophageal cancer	0.00122	0.00255	CcSEcCtD
Aprepitant—Abdominal discomfort—Capecitabine—esophageal cancer	0.00121	0.00255	CcSEcCtD
Aprepitant—Erythema—Cisplatin—esophageal cancer	0.0012	0.00251	CcSEcCtD
Aprepitant—Malnutrition—Cisplatin—esophageal cancer	0.0012	0.00251	CcSEcCtD
Aprepitant—Neutropenia—Capecitabine—esophageal cancer	0.00118	0.00248	CcSEcCtD
Aprepitant—Dysuria—Capecitabine—esophageal cancer	0.00118	0.00248	CcSEcCtD
Aprepitant—Flatulence—Cisplatin—esophageal cancer	0.00118	0.00247	CcSEcCtD
Aprepitant—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.00118	0.00247	CcSEcCtD
Aprepitant—Photosensitivity reaction—Capecitabine—esophageal cancer	0.00116	0.00242	CcSEcCtD
Aprepitant—Weight increased—Capecitabine—esophageal cancer	0.00115	0.00242	CcSEcCtD
Aprepitant—Muscle spasms—Cisplatin—esophageal cancer	0.00115	0.00241	CcSEcCtD
Aprepitant—Weight decreased—Capecitabine—esophageal cancer	0.00115	0.0024	CcSEcCtD
Aprepitant—Hyperglycaemia—Capecitabine—esophageal cancer	0.00114	0.00239	CcSEcCtD
Aprepitant—Pneumonia—Capecitabine—esophageal cancer	0.00114	0.00238	CcSEcCtD
Aprepitant—Infestation—Capecitabine—esophageal cancer	0.00113	0.00237	CcSEcCtD
Aprepitant—Infestation NOS—Capecitabine—esophageal cancer	0.00113	0.00237	CcSEcCtD
Aprepitant—Tremor—Cisplatin—esophageal cancer	0.00112	0.00235	CcSEcCtD
Aprepitant—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.00112	0.00235	CcSEcCtD
Aprepitant—Acute coronary syndrome—Capecitabine—esophageal cancer	0.00111	0.00233	CcSEcCtD
Aprepitant—Lethargy—Methotrexate—esophageal cancer	0.00111	0.00233	CcSEcCtD
Aprepitant—Ill-defined disorder—Cisplatin—esophageal cancer	0.00111	0.00233	CcSEcCtD
Aprepitant—Renal failure—Capecitabine—esophageal cancer	0.00111	0.00233	CcSEcCtD
Aprepitant—Neuropathy peripheral—Capecitabine—esophageal cancer	0.00111	0.00232	CcSEcCtD
Aprepitant—Myocardial infarction—Capecitabine—esophageal cancer	0.00111	0.00232	CcSEcCtD
Aprepitant—Anaemia—Cisplatin—esophageal cancer	0.00111	0.00232	CcSEcCtD
Aprepitant—Stomatitis—Capecitabine—esophageal cancer	0.0011	0.00231	CcSEcCtD
Aprepitant—Conjunctivitis—Capecitabine—esophageal cancer	0.0011	0.0023	CcSEcCtD
Aprepitant—Urinary tract infection—Capecitabine—esophageal cancer	0.0011	0.0023	CcSEcCtD
Aprepitant—Osteoarthritis—Methotrexate—esophageal cancer	0.00109	0.00229	CcSEcCtD
Aprepitant—Malaise—Cisplatin—esophageal cancer	0.00108	0.00226	CcSEcCtD
Aprepitant—Haematuria—Capecitabine—esophageal cancer	0.00108	0.00226	CcSEcCtD
Aprepitant—Convulsion—Cisplatin—esophageal cancer	0.00104	0.00217	CcSEcCtD
Aprepitant—Bradycardia—Capecitabine—esophageal cancer	0.00103	0.00216	CcSEcCtD
Aprepitant—Myalgia—Cisplatin—esophageal cancer	0.00102	0.00214	CcSEcCtD
Aprepitant—Anxiety—Cisplatin—esophageal cancer	0.00102	0.00213	CcSEcCtD
Aprepitant—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.00101	0.00212	CcSEcCtD
Aprepitant—Hypoaesthesia—Capecitabine—esophageal cancer	0.00101	0.00211	CcSEcCtD
Aprepitant—Discomfort—Cisplatin—esophageal cancer	0.00101	0.00211	CcSEcCtD
Aprepitant—Pharyngitis—Capecitabine—esophageal cancer	0.00101	0.00211	CcSEcCtD
Aprepitant—Urinary tract disorder—Capecitabine—esophageal cancer	0.001	0.0021	CcSEcCtD
Aprepitant—Connective tissue disorder—Capecitabine—esophageal cancer	0.000997	0.00209	CcSEcCtD
Aprepitant—Urethral disorder—Capecitabine—esophageal cancer	0.000994	0.00208	CcSEcCtD
Aprepitant—Breast disorder—Methotrexate—esophageal cancer	0.000986	0.00207	CcSEcCtD
Aprepitant—Toxic epidermal necrolysis—Methotrexate—esophageal cancer	0.000983	0.00206	CcSEcCtD
Aprepitant—Oedema—Cisplatin—esophageal cancer	0.000977	0.00205	CcSEcCtD
Aprepitant—Anaphylactic shock—Cisplatin—esophageal cancer	0.000977	0.00205	CcSEcCtD
Aprepitant—Infection—Cisplatin—esophageal cancer	0.000971	0.00203	CcSEcCtD
Aprepitant—Erythema multiforme—Capecitabine—esophageal cancer	0.000959	0.00201	CcSEcCtD
Aprepitant—Nervous system disorder—Cisplatin—esophageal cancer	0.000959	0.00201	CcSEcCtD
Aprepitant—Thrombocytopenia—Cisplatin—esophageal cancer	0.000957	0.00201	CcSEcCtD
Aprepitant—Tachycardia—Cisplatin—esophageal cancer	0.000954	0.002	CcSEcCtD
Aprepitant—Skin disorder—Cisplatin—esophageal cancer	0.000949	0.00199	CcSEcCtD
Aprepitant—Eye disorder—Capecitabine—esophageal cancer	0.000948	0.00199	CcSEcCtD
Aprepitant—Tinnitus—Capecitabine—esophageal cancer	0.000946	0.00198	CcSEcCtD
Aprepitant—Hyperhidrosis—Cisplatin—esophageal cancer	0.000945	0.00198	CcSEcCtD
Aprepitant—Cardiac disorder—Capecitabine—esophageal cancer	0.000941	0.00197	CcSEcCtD
Aprepitant—Flushing—Capecitabine—esophageal cancer	0.000941	0.00197	CcSEcCtD
Aprepitant—Anorexia—Cisplatin—esophageal cancer	0.000932	0.00195	CcSEcCtD
Aprepitant—Angiopathy—Capecitabine—esophageal cancer	0.00092	0.00193	CcSEcCtD
Aprepitant—Immune system disorder—Capecitabine—esophageal cancer	0.000916	0.00192	CcSEcCtD
Aprepitant—Mediastinal disorder—Capecitabine—esophageal cancer	0.000914	0.00192	CcSEcCtD
Aprepitant—Hypotension—Cisplatin—esophageal cancer	0.000913	0.00191	CcSEcCtD
Aprepitant—Chills—Capecitabine—esophageal cancer	0.00091	0.00191	CcSEcCtD
Aprepitant—Abdominal discomfort—Methotrexate—esophageal cancer	0.000904	0.00189	CcSEcCtD
Aprepitant—Alopecia—Capecitabine—esophageal cancer	0.000896	0.00188	CcSEcCtD
Aprepitant—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000891	0.00187	CcSEcCtD
Aprepitant—Mental disorder—Capecitabine—esophageal cancer	0.000889	0.00186	CcSEcCtD
Aprepitant—Erythema—Capecitabine—esophageal cancer	0.000883	0.00185	CcSEcCtD
Aprepitant—Malnutrition—Capecitabine—esophageal cancer	0.000883	0.00185	CcSEcCtD
Aprepitant—Neutropenia—Methotrexate—esophageal cancer	0.000882	0.00185	CcSEcCtD
Aprepitant—Dysuria—Methotrexate—esophageal cancer	0.000882	0.00185	CcSEcCtD
Aprepitant—Paraesthesia—Cisplatin—esophageal cancer	0.000878	0.00184	CcSEcCtD
Aprepitant—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.000877	0.00184	CcSEcCtD
Aprepitant—Dyspnoea—Cisplatin—esophageal cancer	0.000871	0.00183	CcSEcCtD
Aprepitant—Flatulence—Capecitabine—esophageal cancer	0.00087	0.00182	CcSEcCtD
Aprepitant—Dysgeusia—Capecitabine—esophageal cancer	0.000865	0.00181	CcSEcCtD
Aprepitant—Photosensitivity reaction—Methotrexate—esophageal cancer	0.000861	0.0018	CcSEcCtD
Aprepitant—Back pain—Capecitabine—esophageal cancer	0.000854	0.00179	CcSEcCtD
Aprepitant—Decreased appetite—Cisplatin—esophageal cancer	0.00085	0.00178	CcSEcCtD
Aprepitant—Muscle spasms—Capecitabine—esophageal cancer	0.000849	0.00178	CcSEcCtD
Aprepitant—Pneumonia—Methotrexate—esophageal cancer	0.000846	0.00177	CcSEcCtD
Aprepitant—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000844	0.00177	CcSEcCtD
Aprepitant—Infestation NOS—Methotrexate—esophageal cancer	0.000841	0.00176	CcSEcCtD
Aprepitant—Infestation—Methotrexate—esophageal cancer	0.000841	0.00176	CcSEcCtD
Aprepitant—Pain—Cisplatin—esophageal cancer	0.000836	0.00175	CcSEcCtD
Aprepitant—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	0.000834	0.00175	CcSEcCtD
Aprepitant—Tremor—Capecitabine—esophageal cancer	0.000827	0.00173	CcSEcCtD
Aprepitant—Renal failure—Methotrexate—esophageal cancer	0.000827	0.00173	CcSEcCtD
Aprepitant—Stomatitis—Methotrexate—esophageal cancer	0.00082	0.00172	CcSEcCtD
Aprepitant—Ill-defined disorder—Capecitabine—esophageal cancer	0.000819	0.00172	CcSEcCtD
Aprepitant—Conjunctivitis—Methotrexate—esophageal cancer	0.000817	0.00171	CcSEcCtD
Aprepitant—Anaemia—Capecitabine—esophageal cancer	0.000816	0.00171	CcSEcCtD
Aprepitant—Feeling abnormal—Cisplatin—esophageal cancer	0.000805	0.00169	CcSEcCtD
Aprepitant—Haematuria—Methotrexate—esophageal cancer	0.000802	0.00168	CcSEcCtD
Aprepitant—Malaise—Capecitabine—esophageal cancer	0.000796	0.00167	CcSEcCtD
Aprepitant—Syncope—Capecitabine—esophageal cancer	0.000792	0.00166	CcSEcCtD
Aprepitant—Palpitations—Capecitabine—esophageal cancer	0.00078	0.00163	CcSEcCtD
Aprepitant—Loss of consciousness—Capecitabine—esophageal cancer	0.000776	0.00163	CcSEcCtD
Aprepitant—Body temperature increased—Cisplatin—esophageal cancer	0.000773	0.00162	CcSEcCtD
Aprepitant—Cough—Capecitabine—esophageal cancer	0.00077	0.00161	CcSEcCtD
Aprepitant—Hypertension—Capecitabine—esophageal cancer	0.000762	0.0016	CcSEcCtD
Aprepitant—Chest pain—Capecitabine—esophageal cancer	0.000752	0.00157	CcSEcCtD
Aprepitant—Myalgia—Capecitabine—esophageal cancer	0.000752	0.00157	CcSEcCtD
Aprepitant—Arthralgia—Capecitabine—esophageal cancer	0.000752	0.00157	CcSEcCtD
Aprepitant—Pharyngitis—Methotrexate—esophageal cancer	0.000749	0.00157	CcSEcCtD
Aprepitant—Anxiety—Capecitabine—esophageal cancer	0.000749	0.00157	CcSEcCtD
Aprepitant—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000746	0.00156	CcSEcCtD
Aprepitant—Urinary tract disorder—Methotrexate—esophageal cancer	0.000746	0.00156	CcSEcCtD
Aprepitant—Discomfort—Capecitabine—esophageal cancer	0.000743	0.00156	CcSEcCtD
Aprepitant—Urethral disorder—Methotrexate—esophageal cancer	0.00074	0.00155	CcSEcCtD
Aprepitant—Dry mouth—Capecitabine—esophageal cancer	0.000735	0.00154	CcSEcCtD
Aprepitant—Confusional state—Capecitabine—esophageal cancer	0.000727	0.00152	CcSEcCtD
Aprepitant—Oedema—Capecitabine—esophageal cancer	0.000721	0.00151	CcSEcCtD
Aprepitant—Hypersensitivity—Cisplatin—esophageal cancer	0.00072	0.00151	CcSEcCtD
Aprepitant—Infection—Capecitabine—esophageal cancer	0.000716	0.0015	CcSEcCtD
Aprepitant—Erythema multiforme—Methotrexate—esophageal cancer	0.000714	0.0015	CcSEcCtD
Aprepitant—Shock—Capecitabine—esophageal cancer	0.000709	0.00149	CcSEcCtD
Aprepitant—Nervous system disorder—Capecitabine—esophageal cancer	0.000707	0.00148	CcSEcCtD
Aprepitant—Eye disorder—Methotrexate—esophageal cancer	0.000706	0.00148	CcSEcCtD
Aprepitant—Thrombocytopenia—Capecitabine—esophageal cancer	0.000705	0.00148	CcSEcCtD
Aprepitant—Tinnitus—Methotrexate—esophageal cancer	0.000704	0.00147	CcSEcCtD
Aprepitant—Tachycardia—Capecitabine—esophageal cancer	0.000703	0.00147	CcSEcCtD
Aprepitant—Asthenia—Cisplatin—esophageal cancer	0.000701	0.00147	CcSEcCtD
Aprepitant—Cardiac disorder—Methotrexate—esophageal cancer	0.000701	0.00147	CcSEcCtD
Aprepitant—Skin disorder—Capecitabine—esophageal cancer	0.0007	0.00147	CcSEcCtD
Aprepitant—Hyperhidrosis—Capecitabine—esophageal cancer	0.000697	0.00146	CcSEcCtD
Aprepitant—Anorexia—Capecitabine—esophageal cancer	0.000687	0.00144	CcSEcCtD
Aprepitant—Angiopathy—Methotrexate—esophageal cancer	0.000685	0.00144	CcSEcCtD
Aprepitant—Immune system disorder—Methotrexate—esophageal cancer	0.000682	0.00143	CcSEcCtD
Aprepitant—Mediastinal disorder—Methotrexate—esophageal cancer	0.00068	0.00143	CcSEcCtD
Aprepitant—Chills—Methotrexate—esophageal cancer	0.000677	0.00142	CcSEcCtD
Aprepitant—Hypotension—Capecitabine—esophageal cancer	0.000673	0.00141	CcSEcCtD
Aprepitant—Diarrhoea—Cisplatin—esophageal cancer	0.000669	0.0014	CcSEcCtD
Aprepitant—Alopecia—Methotrexate—esophageal cancer	0.000667	0.0014	CcSEcCtD
Aprepitant—Mental disorder—Methotrexate—esophageal cancer	0.000661	0.00139	CcSEcCtD
Aprepitant—Malnutrition—Methotrexate—esophageal cancer	0.000657	0.00138	CcSEcCtD
Aprepitant—Erythema—Methotrexate—esophageal cancer	0.000657	0.00138	CcSEcCtD
Aprepitant—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000656	0.00138	CcSEcCtD
Aprepitant—Insomnia—Capecitabine—esophageal cancer	0.000652	0.00137	CcSEcCtD
Aprepitant—Paraesthesia—Capecitabine—esophageal cancer	0.000647	0.00136	CcSEcCtD
Aprepitant—Dysgeusia—Methotrexate—esophageal cancer	0.000644	0.00135	CcSEcCtD
Aprepitant—Dyspnoea—Capecitabine—esophageal cancer	0.000642	0.00135	CcSEcCtD
Aprepitant—Back pain—Methotrexate—esophageal cancer	0.000636	0.00133	CcSEcCtD
Aprepitant—Dyspepsia—Capecitabine—esophageal cancer	0.000634	0.00133	CcSEcCtD
Aprepitant—Decreased appetite—Capecitabine—esophageal cancer	0.000626	0.00131	CcSEcCtD
Aprepitant—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000622	0.0013	CcSEcCtD
Aprepitant—Vomiting—Cisplatin—esophageal cancer	0.000621	0.0013	CcSEcCtD
Aprepitant—Fatigue—Capecitabine—esophageal cancer	0.000621	0.0013	CcSEcCtD
Aprepitant—Rash—Cisplatin—esophageal cancer	0.000616	0.00129	CcSEcCtD
Aprepitant—Pain—Capecitabine—esophageal cancer	0.000616	0.00129	CcSEcCtD
Aprepitant—Constipation—Capecitabine—esophageal cancer	0.000616	0.00129	CcSEcCtD
Aprepitant—Dermatitis—Cisplatin—esophageal cancer	0.000616	0.00129	CcSEcCtD
Aprepitant—Ill-defined disorder—Methotrexate—esophageal cancer	0.00061	0.00128	CcSEcCtD
Aprepitant—Anaemia—Methotrexate—esophageal cancer	0.000607	0.00127	CcSEcCtD
Aprepitant—Feeling abnormal—Capecitabine—esophageal cancer	0.000594	0.00124	CcSEcCtD
Aprepitant—Malaise—Methotrexate—esophageal cancer	0.000593	0.00124	CcSEcCtD
Aprepitant—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000589	0.00123	CcSEcCtD
Aprepitant—Nausea—Cisplatin—esophageal cancer	0.000581	0.00122	CcSEcCtD
Aprepitant—Cough—Methotrexate—esophageal cancer	0.000574	0.0012	CcSEcCtD
Aprepitant—Urticaria—Capecitabine—esophageal cancer	0.000572	0.0012	CcSEcCtD
Aprepitant—Abdominal pain—Capecitabine—esophageal cancer	0.00057	0.00119	CcSEcCtD
Aprepitant—Body temperature increased—Capecitabine—esophageal cancer	0.00057	0.00119	CcSEcCtD
Aprepitant—Convulsion—Methotrexate—esophageal cancer	0.000569	0.00119	CcSEcCtD
Aprepitant—Chest pain—Methotrexate—esophageal cancer	0.00056	0.00117	CcSEcCtD
Aprepitant—Arthralgia—Methotrexate—esophageal cancer	0.00056	0.00117	CcSEcCtD
Aprepitant—Myalgia—Methotrexate—esophageal cancer	0.00056	0.00117	CcSEcCtD
Aprepitant—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000556	0.00116	CcSEcCtD
Aprepitant—Discomfort—Methotrexate—esophageal cancer	0.000553	0.00116	CcSEcCtD
Aprepitant—Confusional state—Methotrexate—esophageal cancer	0.000541	0.00113	CcSEcCtD
Aprepitant—Anaphylactic shock—Methotrexate—esophageal cancer	0.000536	0.00112	CcSEcCtD
Aprepitant—Infection—Methotrexate—esophageal cancer	0.000533	0.00112	CcSEcCtD
Aprepitant—Hypersensitivity—Capecitabine—esophageal cancer	0.000531	0.00111	CcSEcCtD
Aprepitant—Nervous system disorder—Methotrexate—esophageal cancer	0.000526	0.0011	CcSEcCtD
Aprepitant—Thrombocytopenia—Methotrexate—esophageal cancer	0.000525	0.0011	CcSEcCtD
Aprepitant—Skin disorder—Methotrexate—esophageal cancer	0.000521	0.00109	CcSEcCtD
Aprepitant—Hyperhidrosis—Methotrexate—esophageal cancer	0.000519	0.00109	CcSEcCtD
Aprepitant—Asthenia—Capecitabine—esophageal cancer	0.000517	0.00108	CcSEcCtD
Aprepitant—Anorexia—Methotrexate—esophageal cancer	0.000511	0.00107	CcSEcCtD
Aprepitant—Pruritus—Capecitabine—esophageal cancer	0.00051	0.00107	CcSEcCtD
Aprepitant—Hypotension—Methotrexate—esophageal cancer	0.000501	0.00105	CcSEcCtD
Aprepitant—Diarrhoea—Capecitabine—esophageal cancer	0.000493	0.00103	CcSEcCtD
Aprepitant—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000489	0.00102	CcSEcCtD
Aprepitant—Insomnia—Methotrexate—esophageal cancer	0.000485	0.00102	CcSEcCtD
Aprepitant—Paraesthesia—Methotrexate—esophageal cancer	0.000482	0.00101	CcSEcCtD
Aprepitant—Dyspnoea—Methotrexate—esophageal cancer	0.000478	0.001	CcSEcCtD
Aprepitant—Somnolence—Methotrexate—esophageal cancer	0.000477	0.000999	CcSEcCtD
Aprepitant—Dizziness—Capecitabine—esophageal cancer	0.000476	0.000998	CcSEcCtD
Aprepitant—Dyspepsia—Methotrexate—esophageal cancer	0.000472	0.000989	CcSEcCtD
Aprepitant—Decreased appetite—Methotrexate—esophageal cancer	0.000466	0.000977	CcSEcCtD
Aprepitant—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000463	0.00097	CcSEcCtD
Aprepitant—Fatigue—Methotrexate—esophageal cancer	0.000462	0.000969	CcSEcCtD
Aprepitant—Pain—Methotrexate—esophageal cancer	0.000459	0.000961	CcSEcCtD
Aprepitant—Vomiting—Capecitabine—esophageal cancer	0.000458	0.00096	CcSEcCtD
Aprepitant—Rash—Capecitabine—esophageal cancer	0.000454	0.000952	CcSEcCtD
Aprepitant—Dermatitis—Capecitabine—esophageal cancer	0.000454	0.000951	CcSEcCtD
Aprepitant—Headache—Capecitabine—esophageal cancer	0.000451	0.000946	CcSEcCtD
Aprepitant—Feeling abnormal—Methotrexate—esophageal cancer	0.000442	0.000926	CcSEcCtD
Aprepitant—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000439	0.000919	CcSEcCtD
Aprepitant—Nausea—Capecitabine—esophageal cancer	0.000428	0.000897	CcSEcCtD
Aprepitant—Urticaria—Methotrexate—esophageal cancer	0.000426	0.000893	CcSEcCtD
Aprepitant—Body temperature increased—Methotrexate—esophageal cancer	0.000424	0.000888	CcSEcCtD
Aprepitant—Abdominal pain—Methotrexate—esophageal cancer	0.000424	0.000888	CcSEcCtD
Aprepitant—Hypersensitivity—Methotrexate—esophageal cancer	0.000395	0.000828	CcSEcCtD
Aprepitant—Asthenia—Methotrexate—esophageal cancer	0.000385	0.000806	CcSEcCtD
Aprepitant—Pruritus—Methotrexate—esophageal cancer	0.000379	0.000795	CcSEcCtD
Aprepitant—Diarrhoea—Methotrexate—esophageal cancer	0.000367	0.000769	CcSEcCtD
Aprepitant—Dizziness—Methotrexate—esophageal cancer	0.000355	0.000743	CcSEcCtD
Aprepitant—Vomiting—Methotrexate—esophageal cancer	0.000341	0.000715	CcSEcCtD
Aprepitant—Rash—Methotrexate—esophageal cancer	0.000338	0.000709	CcSEcCtD
Aprepitant—Dermatitis—Methotrexate—esophageal cancer	0.000338	0.000708	CcSEcCtD
Aprepitant—Headache—Methotrexate—esophageal cancer	0.000336	0.000704	CcSEcCtD
Aprepitant—Nausea—Methotrexate—esophageal cancer	0.000319	0.000668	CcSEcCtD
Aprepitant—TACR3—Signaling Pathways—ERBB2—esophageal cancer	0.000161	0.000422	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—ADH7—esophageal cancer	0.000157	0.00041	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—PLCE1—esophageal cancer	0.000157	0.00041	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—BLVRB—esophageal cancer	0.000157	0.00041	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—SLC52A3—esophageal cancer	0.000157	0.00041	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	0.000156	0.000409	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—TGFBR2—esophageal cancer	0.000149	0.000389	CbGpPWpGaD
Aprepitant—CYP3A4—Biological oxidations—CYP1B1—esophageal cancer	0.000144	0.000377	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—CCND1—esophageal cancer	0.000142	0.000373	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	0.000142	0.000373	CbGpPWpGaD
Aprepitant—CYP3A4—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000142	0.000372	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—SMAD4—esophageal cancer	0.000141	0.000368	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—CDKN1A—esophageal cancer	0.000138	0.000361	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—ADH1B—esophageal cancer	0.000137	0.00036	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	0.000136	0.000357	CbGpPWpGaD
Aprepitant—CYP3A4—Biological oxidations—CYP19A1—esophageal cancer	0.000135	0.000355	CbGpPWpGaD
Aprepitant—CYP3A4—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000134	0.00035	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—SLC10A2—esophageal cancer	0.000133	0.000349	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—CA1—esophageal cancer	0.000133	0.000349	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—TYMP—esophageal cancer	0.000131	0.000344	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—EP300—esophageal cancer	0.000131	0.000343	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—CYP26A1—esophageal cancer	0.000128	0.000334	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—ALOX15—esophageal cancer	0.000124	0.000326	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	0.000124	0.000325	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—CA2—esophageal cancer	0.000122	0.000319	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	0.000122	0.000319	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—BLVRB—esophageal cancer	0.000121	0.000317	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—SLC52A3—esophageal cancer	0.000121	0.000317	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—TPI1—esophageal cancer	0.000119	0.000311	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—GSTO1—esophageal cancer	0.000119	0.000311	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—HIF1A—esophageal cancer	0.000115	0.000301	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—MYC—esophageal cancer	0.000114	0.000299	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—ALDOB—esophageal cancer	0.000114	0.000298	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—PLCE1—esophageal cancer	0.000113	0.000296	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—ADH7—esophageal cancer	0.000113	0.000296	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—EGFR—esophageal cancer	0.000112	0.000293	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—BLVRB—esophageal cancer	0.00011	0.000289	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—SLC52A3—esophageal cancer	0.00011	0.000289	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—KDR—esophageal cancer	0.00011	0.000288	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—GAPDH—esophageal cancer	0.000109	0.000287	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—CRABP1—esophageal cancer	0.000108	0.000284	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	0.000108	0.000283	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	0.000106	0.000278	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—NOTCH1—esophageal cancer	0.000104	0.000271	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—GNG7—esophageal cancer	0.000103	0.00027	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—SLC10A2—esophageal cancer	0.000103	0.00027	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—CA1—esophageal cancer	0.000103	0.00027	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—ADH1B—esophageal cancer	9.92e-05	0.00026	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	9.86e-05	0.000258	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—PIK3CA—esophageal cancer	9.69e-05	0.000254	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—ALDH2—esophageal cancer	9.67e-05	0.000253	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—TYMP—esophageal cancer	9.48e-05	0.000248	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—BLVRB—esophageal cancer	9.43e-05	0.000247	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—SLC52A3—esophageal cancer	9.43e-05	0.000247	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—CA2—esophageal cancer	9.41e-05	0.000247	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—CREBBP—esophageal cancer	9.4e-05	0.000246	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—CA1—esophageal cancer	9.38e-05	0.000246	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—SLC10A2—esophageal cancer	9.38e-05	0.000246	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—TP53—esophageal cancer	9.38e-05	0.000246	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—EGFR—esophageal cancer	9.23e-05	0.000242	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—CYP26A1—esophageal cancer	9.22e-05	0.000242	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—GSTT1—esophageal cancer	9.2e-05	0.000241	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	9.2e-05	0.000241	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—CYP2A6—esophageal cancer	9.09e-05	0.000238	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—ALOX15—esophageal cancer	8.99e-05	0.000236	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—PIK3CA—esophageal cancer	8.82e-05	0.000231	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—PLCE1—esophageal cancer	8.75e-05	0.000229	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—ADH7—esophageal cancer	8.75e-05	0.000229	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	8.65e-05	0.000227	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—ENO1—esophageal cancer	8.62e-05	0.000226	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—PTGS1—esophageal cancer	8.62e-05	0.000226	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—CA2—esophageal cancer	8.58e-05	0.000225	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—TPI1—esophageal cancer	8.58e-05	0.000225	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—GSTO1—esophageal cancer	8.58e-05	0.000225	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—PSME2—esophageal cancer	8.49e-05	0.000223	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—PSME1—esophageal cancer	8.49e-05	0.000223	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	8.43e-05	0.000221	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—NOS3—esophageal cancer	8.41e-05	0.00022	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	8.39e-05	0.00022	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—ALDOB—esophageal cancer	8.22e-05	0.000215	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—SLC10A2—esophageal cancer	8.02e-05	0.00021	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—CA1—esophageal cancer	8.02e-05	0.00021	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—PIK3CA—esophageal cancer	8.01e-05	0.00021	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—ADH7—esophageal cancer	7.98e-05	0.000209	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—PLCE1—esophageal cancer	7.98e-05	0.000209	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—GAPDH—esophageal cancer	7.91e-05	0.000207	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	7.88e-05	0.000207	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—ERBB2—esophageal cancer	7.87e-05	0.000206	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—CRABP1—esophageal cancer	7.84e-05	0.000205	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—ADH1B—esophageal cancer	7.67e-05	0.000201	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—GNG7—esophageal cancer	7.46e-05	0.000195	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—CA2—esophageal cancer	7.33e-05	0.000192	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—TYMP—esophageal cancer	7.33e-05	0.000192	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—CYP1B1—esophageal cancer	7.33e-05	0.000192	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—BLVRB—esophageal cancer	7.28e-05	0.000191	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—SLC52A3—esophageal cancer	7.28e-05	0.000191	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	7.17e-05	0.000188	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—CYP26A1—esophageal cancer	7.13e-05	0.000187	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—ADH1B—esophageal cancer	6.99e-05	0.000183	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—ALDH2—esophageal cancer	6.99e-05	0.000183	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—CCND1—esophageal cancer	6.95e-05	0.000182	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—ALOX15—esophageal cancer	6.95e-05	0.000182	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—CYP19A1—esophageal cancer	6.89e-05	0.000181	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—ADH7—esophageal cancer	6.82e-05	0.000179	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—PLCE1—esophageal cancer	6.82e-05	0.000179	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	6.74e-05	0.000177	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—CDKN1A—esophageal cancer	6.72e-05	0.000176	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—TYMP—esophageal cancer	6.68e-05	0.000175	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—GSTT1—esophageal cancer	6.65e-05	0.000174	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—GSTO1—esophageal cancer	6.63e-05	0.000174	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—TPI1—esophageal cancer	6.63e-05	0.000174	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—CYP2A6—esophageal cancer	6.57e-05	0.000172	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—CYP26A1—esophageal cancer	6.5e-05	0.00017	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—EP300—esophageal cancer	6.4e-05	0.000168	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—ALDOB—esophageal cancer	6.36e-05	0.000167	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—ALOX15—esophageal cancer	6.34e-05	0.000166	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—HMOX1—esophageal cancer	6.29e-05	0.000165	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—PTGS1—esophageal cancer	6.23e-05	0.000163	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—ENO1—esophageal cancer	6.23e-05	0.000163	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—CA1—esophageal cancer	6.19e-05	0.000162	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—SLC10A2—esophageal cancer	6.19e-05	0.000162	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—PSME1—esophageal cancer	6.14e-05	0.000161	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—PSME2—esophageal cancer	6.14e-05	0.000161	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—GAPDH—esophageal cancer	6.12e-05	0.00016	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—CRABP1—esophageal cancer	6.06e-05	0.000159	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—TPI1—esophageal cancer	6.04e-05	0.000158	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—GSTO1—esophageal cancer	6.04e-05	0.000158	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—ABCB1—esophageal cancer	6.04e-05	0.000158	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—ADH1B—esophageal cancer	5.98e-05	0.000157	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—ALDOB—esophageal cancer	5.8e-05	0.000152	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—GNG7—esophageal cancer	5.77e-05	0.000151	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—TYMP—esophageal cancer	5.71e-05	0.00015	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—CA2—esophageal cancer	5.66e-05	0.000148	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—GAPDH—esophageal cancer	5.58e-05	0.000146	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—MYC—esophageal cancer	5.58e-05	0.000146	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—CYP26A1—esophageal cancer	5.56e-05	0.000146	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—CRABP1—esophageal cancer	5.53e-05	0.000145	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—EGFR—esophageal cancer	5.45e-05	0.000143	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—ALOX15—esophageal cancer	5.41e-05	0.000142	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—ALDH2—esophageal cancer	5.4e-05	0.000142	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—CYP1B1—esophageal cancer	5.3e-05	0.000139	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—PLCE1—esophageal cancer	5.26e-05	0.000138	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—ADH7—esophageal cancer	5.26e-05	0.000138	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—GNG7—esophageal cancer	5.26e-05	0.000138	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—TPI1—esophageal cancer	5.17e-05	0.000135	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—GSTO1—esophageal cancer	5.17e-05	0.000135	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—GSTT1—esophageal cancer	5.14e-05	0.000135	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—CYP2A6—esophageal cancer	5.08e-05	0.000133	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	5.06e-05	0.000133	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—CYP19A1—esophageal cancer	4.98e-05	0.00013	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—ALDOB—esophageal cancer	4.95e-05	0.00013	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—ALDH2—esophageal cancer	4.93e-05	0.000129	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—PTGS1—esophageal cancer	4.82e-05	0.000126	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—ENO1—esophageal cancer	4.82e-05	0.000126	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—GAPDH—esophageal cancer	4.77e-05	0.000125	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—PSME2—esophageal cancer	4.75e-05	0.000124	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—PSME1—esophageal cancer	4.75e-05	0.000124	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—PIK3CA—esophageal cancer	4.73e-05	0.000124	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—CRABP1—esophageal cancer	4.72e-05	0.000124	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—GSTT1—esophageal cancer	4.69e-05	0.000123	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—CYP2A6—esophageal cancer	4.63e-05	0.000121	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	4.62e-05	0.000121	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—ADH1B—esophageal cancer	4.61e-05	0.000121	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—TP53—esophageal cancer	4.58e-05	0.00012	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—HMOX1—esophageal cancer	4.55e-05	0.000119	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—GNG7—esophageal cancer	4.49e-05	0.000118	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—TYMP—esophageal cancer	4.41e-05	0.000115	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—ENO1—esophageal cancer	4.39e-05	0.000115	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—PTGS1—esophageal cancer	4.39e-05	0.000115	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—ABCB1—esophageal cancer	4.36e-05	0.000114	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—PSME1—esophageal cancer	4.33e-05	0.000113	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—PSME2—esophageal cancer	4.33e-05	0.000113	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—CYP26A1—esophageal cancer	4.29e-05	0.000112	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—ALDH2—esophageal cancer	4.21e-05	0.00011	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—ALOX15—esophageal cancer	4.18e-05	0.000109	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	4.14e-05	0.000109	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—CYP1B1—esophageal cancer	4.1e-05	0.000107	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—CREBBP—esophageal cancer	4.03e-05	0.000106	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—GSTT1—esophageal cancer	4.01e-05	0.000105	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—TPI1—esophageal cancer	3.99e-05	0.000104	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—GSTO1—esophageal cancer	3.99e-05	0.000104	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—CYP2A6—esophageal cancer	3.96e-05	0.000104	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	3.94e-05	0.000103	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—CYP19A1—esophageal cancer	3.85e-05	0.000101	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—ALDOB—esophageal cancer	3.82e-05	0.0001	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	3.78e-05	9.9e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—ENO1—esophageal cancer	3.75e-05	9.83e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—PTGS1—esophageal cancer	3.75e-05	9.83e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—CYP1B1—esophageal cancer	3.73e-05	9.78e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—PSME2—esophageal cancer	3.7e-05	9.69e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—PSME1—esophageal cancer	3.7e-05	9.69e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—GAPDH—esophageal cancer	3.68e-05	9.64e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—CRABP1—esophageal cancer	3.65e-05	9.55e-05	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—NOS3—esophageal cancer	3.61e-05	9.46e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—HMOX1—esophageal cancer	3.51e-05	9.21e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—CYP19A1—esophageal cancer	3.51e-05	9.2e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—GNG7—esophageal cancer	3.47e-05	9.09e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	3.45e-05	9.03e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—ABCB1—esophageal cancer	3.37e-05	8.84e-05	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—PTGS2—esophageal cancer	3.3e-05	8.65e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—ALDH2—esophageal cancer	3.25e-05	8.51e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	3.23e-05	8.46e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—HMOX1—esophageal cancer	3.2e-05	8.39e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—CYP1B1—esophageal cancer	3.19e-05	8.36e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	3.14e-05	8.24e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—GSTT1—esophageal cancer	3.09e-05	8.1e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—ABCB1—esophageal cancer	3.08e-05	8.06e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—CYP2A6—esophageal cancer	3.06e-05	8.01e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—CYP19A1—esophageal cancer	3e-05	7.86e-05	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—CREBBP—esophageal cancer	2.92e-05	7.64e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—PTGS1—esophageal cancer	2.9e-05	7.59e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—ENO1—esophageal cancer	2.9e-05	7.59e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—PSME2—esophageal cancer	2.85e-05	7.48e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—PSME1—esophageal cancer	2.85e-05	7.48e-05	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—EP300—esophageal cancer	2.75e-05	7.2e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—HMOX1—esophageal cancer	2.74e-05	7.17e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	2.69e-05	7.04e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—ABCB1—esophageal cancer	2.63e-05	6.89e-05	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—NOS3—esophageal cancer	2.61e-05	6.84e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	2.55e-05	6.68e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—CYP1B1—esophageal cancer	2.46e-05	6.45e-05	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—PTGS2—esophageal cancer	2.39e-05	6.26e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	2.33e-05	6.09e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—CYP19A1—esophageal cancer	2.32e-05	6.07e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—CREBBP—esophageal cancer	2.25e-05	5.91e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—HMOX1—esophageal cancer	2.11e-05	5.54e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—CREBBP—esophageal cancer	2.06e-05	5.38e-05	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—PIK3CA—esophageal cancer	2.03e-05	5.32e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—ABCB1—esophageal cancer	2.03e-05	5.31e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—NOS3—esophageal cancer	2.02e-05	5.29e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.99e-05	5.21e-05	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—EP300—esophageal cancer	1.99e-05	5.2e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—PTGS2—esophageal cancer	1.85e-05	4.84e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—NOS3—esophageal cancer	1.84e-05	4.82e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—CREBBP—esophageal cancer	1.76e-05	4.6e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—PTGS2—esophageal cancer	1.68e-05	4.41e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—NOS3—esophageal cancer	1.57e-05	4.12e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—EP300—esophageal cancer	1.54e-05	4.02e-05	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—PIK3CA—esophageal cancer	1.47e-05	3.85e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—PTGS2—esophageal cancer	1.44e-05	3.77e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—EP300—esophageal cancer	1.4e-05	3.67e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—CREBBP—esophageal cancer	1.36e-05	3.55e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—NOS3—esophageal cancer	1.21e-05	3.18e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—EP300—esophageal cancer	1.2e-05	3.13e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—PIK3CA—esophageal cancer	1.14e-05	2.98e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—PTGS2—esophageal cancer	1.11e-05	2.91e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—PIK3CA—esophageal cancer	1.04e-05	2.71e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—EP300—esophageal cancer	9.23e-06	2.42e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—PIK3CA—esophageal cancer	8.85e-06	2.32e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—PIK3CA—esophageal cancer	6.83e-06	1.79e-05	CbGpPWpGaD
